

## DAFTAR PUSTAKA

- Abdulrahman GO, et al. (2014). The risk of malignancy index (RMI) women with adnexal masses in Wales. *Taiwanese Journal of Obstetrics & Gynecology* , 376-381.
- Anita Monika Chudecka-Głaz. (2015). ROMA, an algorithm for ovarian cancer. *Clinica Chimica Acta* 440 , 143-151.
- Anton C, et al. (2012). A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. *CLINICAL SCIENCE* (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Obstetrics and Gynecology, São Paulo/SP, Brazil), 437-41.
- Baset A, et al. (2014). Validation of the Risk of Malignancy Index in primary evaluation of ovarian masses. *Middle East Fertility Society Journal* , 324–328.
- Budiana, IN. (2013). Tumor ovarium: prediksi keganasan prabedah. *Jurnal ilmiah kedokteran* , 44 (Divisi Onkologi-Ginekologi, Departemen Obstetri dan Ginekologi FK Unud/RSUP Sanglah Denpasar), 179-85.
- Chan DW, et al. (2009). *Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers*. Washington, United State: the American Association for Clinical Chemistry, Inc.
- Chen WT, et al. (2014). HE4 as a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer. *Asian Pacific Journal of Cancer Prevention* (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center
- Clarke SE, et al. (2009). Risk of Malignancy Index in the Evaluation of Patients With Adnexal Masses. *JOGC* (Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, Dalhousie University, Halifax NS), 440-5.
- Dahlan, S. 2009. Penelitian Diagnostik, dasar-dasar teoritis dan aplikasi dengan program SPSS dan Stata. Seri evidence based medicine 5. Jakarta; Salemba medika.

- Dahlan, S. 2014. Statistik untuk Kedokteran dan Kesehatan. . Seri 1. Edisi 6. Jakarta; Epidemiologi Indonesia
- Fake Li, et al. (2012). Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and Ca125 in predicting epithelial ovarian cancer: A meta-analysis. *BMC Cancer* , 1-18.
- Fujirebio Diagnostics AB. (2011). ROMA, HE4 EIA + ARCHITECT CA 125 II™.
- Gorp V, et al. (2011). HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. *British Journal of Cancer* , 1-8.
- Hertlein L, et al. (2012). Human epididymis protein 4 (HE4) in benign and malignant diseases. *Clin Chem Lab Med* (Department of Obstetrics and Gynecology , University of Munich, Campus Grosshadern, Munich , Germany), 2182-88.
- Jung-Woo Park, et al. (2012). Four Risk of Malignancy Indices in Evaluation of Pelvic Masses. *Korean J Obstet Gynecol* , 636-643.
- Kajiser J, et al. (2013). Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography? *Ultrasound Obstet Gynecol* , 89-97.
- Karlsen MA et al. (2012). Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. *Gynecologic Oncology* , 379–383.
- Kristjansdottir B, et al. (2013). Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. *Gynecologic Oncology* (Elsevier Inc.), 52–58.
- Mansur, S dan Sigit P. 2013. *Modified Gatot Score Has a Better Specificity in Predicting Ovarian Malignancies Compared to Risk Malignancy Index*. Indonesia Obstetri Gynecology Journal Volume 37 No 2 Tahun 2013. Jakarta.
- Mario P and Melichar Bohuslav. (2011). ROMA or death: advances in epithelial ovarian cancer diagnosis. *Clin Chem Lab Med* .

- Menon U, et al. (2005). Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. *Journal Clinical Oncology* , 7919-7926.
- Mofrilindo. (2014). Keakuratan Uji Diagnostik Menggunakan Indeks Risiko Keganasan Dan Indeks Resistensi Neovaskuler Pada Tumor Ovarium. *Tesis*
- Molina R, Jose M, Xavier F, Jaume P. 2011. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. International Society of Oncology and BioMarkers (ISOBM). Department of Gynaecology, Hospital Clínic, Medical School, Barcelona, Spain.
- Moore RG, Brown AK, Miller MC, et al. (2008). The use of multiple novel tumorbiomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. *Gynecol Oncol* , 108:402-8.
- Moore RG, and Allard WJ. (2009). HE4 and CA125 combined for the improved management ovarian cancer. *CLI Oncology* , 20-21.
- Moore RG,et al. (2012). Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *American Journal of Obstetrics & Gynecology* (Department of Obstetrics and Gynecology, and the Department of Pathology and Laboratory Medicine (Dr Steinhoff), Women and Infants Hospital, Alpert Medical School of Brown University, Providence), 351.e1-e8.
- Mulawardhana P, Askandar B, Soehatno. (2011). Perbandingan antara HE4,CA-125, dan Kombinasi HE4 & CA-125 sebagai Tumor Marker pada Pasien Kanker Ovarium Tipe Epitel. *Majalah Obstetri & Ginekologi* (Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Airlangga,RSUD Dr. Soetomo, Surabaya), 81-87.
- Munir SS, Misbah Sultana And Dawood Amin. (2010). The Evaluation Of Pelvic Mass. *Biomedica* , 70-75.
- Ortiz-Munoz B, Aznar-Oroval E, Garcia AG, et al. HE4, CA 125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. *Tumor Biol* 2014;35:7249–58.

- Perkins GL, et al. (2003). Serum Tumor Markers. *American Family Physician* , 1075-82
- Petronella, et al. (2010). Evaluation of the risk of malignancy index in daily clinical management of adnexal masses. *Gynecologic Oncology* , 384–388.
- Prameela, et al. (2015). Role of Risk Malignancy Index in Predicting Ovarian Malignancy and its Correlation with Histopathological Report. *Scholars Journal of Applied Medical Sciences (SJAMS)* , 490-493.
- Putsarat I and Prueksaritanond Nisa. (2013). Evaluation of Four Risk of Malignancy Indices (RMI) in the Preoperative Diagnosis of Ovarian Malignancy at Rajavithi Hospital. *Thai Journal of Obstetrics and Gynaecology* , 163-175.
- Rarung, M. (2008). Sensitivitas dan Spesifisitas Petanda Tumor CA 125 sebagai Prediksi Keganasan Ovarium. *JKM* , 9-14.
- Roche Diagnostics Ltd. (2011). Elecsys® HE4 and CA 125 II and their use in the risk assessment of epithelial ovarian cancer by ROMA (Risk of Ovarian Malignancy Algorithm). *COBAS, COBAS E, LIFE NEEDS ANSWERS* .
- Sandri MT, et al. (2013). Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome. *Gynecologic Oncology* 128 , 233-238.
- Setiadi. 2007. *Konsep & Penulisan Riset Keperawatan*. Yogyakarta: Graha Ilmu
- Sihombing M and Sirait AM. (2007). Angka Ketahanan Hidup Penderita Kanker Ovarium di RS Dr. Cipto Mangunkusumo Jakarta. *Majalah Kedokteran Indonesia* , 345-352.
- Tanamas G, et al. (2014). Risk of Malignancy Index is not accurate as a Triage Tool for Ovarian Cancer. *Indones J Obstet Gynecol* (Division of Oncology Gynecology Department of Obstetrics and Gynecology Faculty of Medicine University of Indonesia/ Dr. Cipto Mangunkusumo Hospital, Jakarta), 51-4.
- Terzić M, et al. (2011). Evaluation of the risk malignancy index diagnostic value in patients with adnexal masses. *Vojnosanit Pregl* .

- Torres JCC, et al. (2002). Risk-of-Malignancy Index in preoperative evaluation of clinically restricted ovarian cancer. *São Paulo Medical Journal* , 73-75.
- Trudel D, et al. (2012, September). Human epididymis protein 4 (HE4) and ovarian cancer prognosis. *Gynecologic Oncology* , 511–515.
- Ulusoy, et al. (2007). The risk of malignancy index in discrimination of adnexal masses. *International Journal of Gynecology and Obstetrics* , 186–191.
- Watcharada M and Pissamai Y. (2009). The Risk of Malignancy Index (RMI) in Diagnosis of Ovarian Malignancy. *Asian Pacific Journal of Cancer Prevention* (Department of Obstetrics and Gynecology, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Thailand), 865-68.
- Winarto H, et al. (2014). Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection in Jakarta, Indonesia. *Asian Pacific Journal of Cancer Prevention* , 1949-1953.
- Yamamoto Y, et al. (2015). Comparison of 4 Risk-of-Malignancy Indexes in the Preoperative Evaluation of Patients With Pelvic Masses: A Prospective Study. *Clinical Ovarian and Other Gynecologic Cancer* , 8-12.
- Yavuzcan A, Mete Çağlar, Emre Ozgü, Yusuf Üstün, Serdar Dilbaz, Ismail Ozdemir, Tayfun Güngör, Selahattin Kumru. (2014). Addition of parity to the risk of malignancy index score in evaluating adnexal masses. *Taiwanese Journal of Obstetrics & Gynecology* 53 (2014) 518 e522
- Yörük P, et al. (2008). Comparison of the Risk of Malignancy Index and Self-Constructed Logistic Regression Models in Preoperative Evaluation of Adnexal Masses. *J Ultrasound Med* , 1469–1477.
- Yurkovetsky Z, et al. (2010). Development of a Multimarker Assay for Early Detection of Ovarian Cancer. *Journal Of Clinical Oncology* , 28 (the University of Pittsburgh), 2159-66.